A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia

Several medications targeting PCSK9 reduce LDL-cholesterol (LDL-C) in heterozygous familial hypercholesterolemia (HeFH). We aimed to assess in patients diagnosed clinically as HeFH, whether LDL-C reduction varied by different therapeutic approaches to PCSK9-targeting or by the underlying genetic variant.

Source: Atherosclerosis - April 12, 2021 Category: Cardiology Authors: Julia Brandts, Kanika I. Dharmayat, Antonio J. Vallejo-Vaz, Mansour Taghavi Azar Sharabiani, Rebecca Jones, John J.P. Kastelein, Frederick J. Raal, Kausik K. Ray Source Type: research